Aurinia PharmaceuticalsAUPH -1.82%82 Gross Margin % is 91.63% as of Mar. 2026, which is 4% below its 10-year median of 95.77. GuruFocus rates AUPH with a GF Score™ of 82/100 and a GF Value™ of $13.97 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 736 Biotechnology companies, Aurinia Pharmaceuticals ranks better than 84.1% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aurinia Pharmaceuticals had a gross margin of 91.63% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Aurinia Pharmaceuticals Gross Margin % Related Terms
Aurinia Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AUPH vs KOD, ABCL, AGIO: Gross Margin % Comparison
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Aurinia Pharmaceuticals (AUPH) has a Gross Margin % of 91.63% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Aurinia Pharmaceuticals and its competitors. This is near median its historical median of 95.77. Over the past decade, Aurinia Pharmaceuticals' Gross Margin % has ranged from 87.99 to 100.24. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #117 out of 736 companies in the Biotechnology industry, placing it in the top 15.9%.
Is Aurinia Pharmaceuticals' Gross Margin % too high?
Aurinia Pharmaceuticals' current Gross Margin % of 91.63% is near median its 10-year median of 95.77. Over the past 10 years, this metric has ranged from a low of 87.99 to a high of 100.24. The Biotechnology industry median Gross Margin % is 60.91. Aurinia Pharmaceuticals' value of 91.63% is 50.4% above this industry median. Based on the distribution chart, Aurinia Pharmaceuticals ranks #117 out of 736 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aurinia Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Gross Margin % compare to KOD and ABCL?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #117 out of 736 companies for Gross Margin %. This places Aurinia Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Aurinia Pharmaceuticals' value of 91.63% is 50.4% above this benchmark. Historically, Aurinia Pharmaceuticals' own Gross Margin % has ranged from 87.99 to 100.24 over the past decade. While the company's 10-year median is 95.77 vs. the industry median of 60.91, Aurinia Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aurinia Pharmaceuticals's current Gross Margin % of 91.63% is 50.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Aurinia Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurinia Pharmaceuticals's current Gross Margin % is 91.63%, which is near median its own 10-year median of 95.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $13.97, compared to a current price of $17.22 — trading 23.3% above its estimated fair value. The current Gross Margin % is 91.63%, which is near median its 10-year median of 95.77 and 50.4% above the Biotechnology industry median of 60.91. Aurinia Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Gross Margin % is 91.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of $17.22 is trading 23.3% above its estimated GF Value™ of $13.97.
GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for AUPH:
Gross Margin %: 91.63% (near median its 10-year median of 95.77)
GF Value™: $13.97 vs. price of $17.22 (23.3% above fair value)
Industry Position: 50.4% above the Biotechnology median (#117 of 736)
No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
82GF Score
Get the complete analysis for AUPH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUPH has been successfully added to your 
